Tetrindole

Tetrindole
Clinical data
ATC code	None;
Identifiers
	IUPAC name 2,3,3a,4,5,6-Hexahydro-8-cyclohexyl-1H-pyrazino[3,2,1-j,k]carbazole;
PubChem CID	160020;
ChemSpider	140675 ;
ChEBI	CHEBI:77799 ;
Chemical and physical data
Formula	C20H26N2
Molar mass	294.442 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CCC(CC1)C2=CC3=C(C=C2)N4CCNC5C4=C3CCC5;
	InChI InChI=1S/C20H26N2/c1-2-5-14(6-3-1)15-9-10-19-17(13-15)16-7-4-8-18-20(16)22(19)12-11-21-18/h9-10,13-14,18,21H,1-8,11-12H2 ; Key:AUXCHYJDVJZEPG-UHFFFAOYSA-N ;
	(what is this?) (verify)

Tetrindole was a drug candidate that functions by reversibly inhibiting monoamine oxidase A; it was first synthesized in Moscow in the early 1990s.^[1] Tetrindole is similar in its chemical structure to pirlindole (Pyrazidol), and metralindole.^[2]

References

^ Medvedev AE, Kirkel AA, Kamyshanskaya NS, Moskvitina TA, Axenova LN, Gorkin VZ, et al. (January 1994). "Monoamine oxidase inhibition by novel antidepressant tetrindole". Biochemical Pharmacology. 47 (2): 303–8. doi:10.1016/0006-2952(94)90021-3. PMID 8304974.
^ Ramsay RR, Gravestock MB (March 2003). "Monoamine oxidases: to inhibit or not to inhibit". Mini Reviews in Medicinal Chemistry. 3 (2): 129–36. doi:10.2174/1389557033405287. PMID 12570845.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.